Loading
A phase 2 trial of Osimertinib, Savolitinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) is a phase 2 interventional study registered as NCT03944772 by AstraZeneca, with 247 participants enrolled, started 2019-06-25 and due to reach its primary completion in 2025-05-06. Interventions recorded: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Savolitinib, Osimertinib, AstraZeneca, Small-cell lung cancer.
Shares Savolitinib, Osimertinib, AstraZeneca, Carboplatin.
Shares Osimertinib, AstraZeneca, Carboplatin, Small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Savolitinib, Durvalumab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Osimertinib, Durvalumab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Carboplatin, Small-cell lung cancer.